INKT MiNK Therapeutics
Price Chart
Executive Summary
MiNK Therapeutics presented data at ASGCT 2026 showing its off-the-shelf iNKT cell therapy, agenT-797, produced context-dependent immune responses (pro-inflammatory in cancer, anti-inflammatory in ARDS) from the same manufacturing batch without genetic engineering. The data supports advancement into a randomized Phase 2 trial in acute lung injury, with preliminary results expected in 2026.
Actionable Insight
The ASGCT data provides mechanistic validation for agenT-797's dual-mode activity, de-risking the platform and supporting the upcoming Phase 2 trial in acute lung injury. Monitor for preliminary Phase 2 data in 2026, which could be a major catalyst. The broad applicability across oncology and critical care expands the addressable market.
Key Facts
- agenT-797 drove TH1 pro-inflammatory immune program in 34 solid tumor patients and TH2 anti-inflammatory response in 20 ARDS patients from the same donor batch.
- Data includes complete metastatic remission in germ cell testicular cancer (agenT-797 + anti-PD-1) and improved survival/pathogen clearance in severe ARDS.
- Favorable safety profile: no uncontrolled cytokine release syndrome or pathologic hyperinflammation.
- Company advancing to randomized Phase 2 trial in acute lung injury (C-1300-02) with preliminary data expected in 2026.
- Manufacturing platform scalable: reproducible across multiple batches and donors, producing billions of cells per donor.
Financial Impact
No financial figures disclosed; potential value depends on Phase 2 trial outcomes and eventual commercialization.
Risk Factors
- Phase 2 trial results may not replicate Phase 1/2 findings.
- Competition from other cell therapy platforms and existing ARDS treatments.
- Regulatory and manufacturing scale-up risks for allogeneic cell therapy.
- Company has limited cash runway (market cap $55M) and may need to raise capital.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292728 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Press Release
| $12.20 $12.76 | ▲ +4.59% | ▲ +4.64% | $11.34 (−7.05%) |
|
May 20, 2026
20d ago
|
Press Release
| $10.72 $10.18 | ▼ −5.04% | ▼ −6.27% | $11.34 (+5.78%) |
|
May 15, 2026
25d ago
|
8-K
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $11.34 (+5.78%) |
|
May 15, 2026
25d ago
|
Press Release
| $10.72 $10.87 | ▲ +1.40% | ▲ +0.44% | $11.34 (+5.78%) |
|
May 14, 2026
26d ago
|
Press Release
| $10.51 $10.94 | ▲ +4.09% | ▲ +4.81% | $11.34 (+7.90%) |
|
May 12, 2026
28d ago
|
Press Release
| $11.41 $10.04 | ▼ −12.01% | ▼ −12.08% | $11.34 (−0.61%) |
|
May 8, 2026
4w ago
|
Press Release
| $10.95 $10.04 | ▼ −8.31% | ▼ −8.23% | $11.34 (+3.56%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $14.21 $10.95 | ▼ −22.94% | ▼ −23.50% | $11.34 (−20.20%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $10.57 $11.47 | ▲ +8.51% | ▲ +4.75% | $11.34 (+7.28%) |
|
Mar 31, 2026
10w ago
|
8-K
| $10.53 $11.15 | ▲ +5.89% | ▲ +1.94% | $11.34 (+7.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access